Selective pharmacotherapeutic inhibition of ANGPTL3 synthesis in patients with T2D, hypertriglyceridemia, and hepatic steatosis significantly lowered triglyceride levels compared to placebo without improving glycemic parameters or hepatic fat content [59]. Here, ANGPTL3 is linked to fatty liver disease.